Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer

PloS One
Michael WhiteRachel L Roper

Abstract

Pancreatic cancer is the 5th leading cause of cancer deaths, and there are no effective treatments. We developed a poxvirus platform vaccine with improved immunogenicity and inserted the mesothelin gene to create an anti-mesothelin cancer vaccine. Mesothelin expression is mostly restricted to tumors in adult mammals and thus may be a good target for cancer treatment. We show here that the modified vaccinia virus Ankara (MVA) virus expressing mesothelin and the enhanced MVA virus missing the immunosuppressive A35 gene and expressing mesothelin were both safe in mice and were able to induce IFN-gamma secreting T cells in response to mesothelin expressing tumor cells. In addition, the MVA virus has oncolytic properties in vitro as it can replicate in and kill Panc02 pancreatic adenocarcinoma cell line tumor cells, even though it is unable to replicate in most mammalian cells. Deletion of the A35 gene in MVA improved T cell responses as expected. However, we were unable to demonstrate inhibition of Panc02 tumor growth in immunocompetent mice with pre-vaccination of mice, boosts, or even intratumoral injections of the recombinant viruses. Vaccine efficacy may be limited by shedding of mesothelin from tumor cells thus creating a prot...Continue Reading

References

Mar 25, 2000·Molecular and Cellular Biology·T K Bera, I Pastan
Jul 19, 2003·Proceedings of the National Academy of Sciences of the United States of America·Igor M BelyakovJay A Berzofsky
Aug 20, 2003·Nature Medicine·Richard WeltzinThomas P Monath
Apr 21, 2004·Proceedings of the National Academy of Sciences of the United States of America·Himani BishtBernard Moss
Dec 30, 2004·The Journal of Experimental Medicine·David C TscharkeJonathan W Yewdell
Aug 6, 2005·Applied Immunohistochemistry & Molecular Morphology : AIMM·Raffit HassanMark C Willingham
Sep 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Junko YokokawaKwong Y Tsang
Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mitchell HoIra Pastan
Jun 22, 2007·Gene Therapy·C-L ChangC-F Hung
Sep 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raffit HassanIra Pastan
Feb 19, 2008·Molecular Cancer Therapeutics·Min LiQizhi Yao
Feb 13, 2009·Proceedings of the National Academy of Sciences of the United States of America·Carmine CarpenitoCarl H June
Oct 16, 2009·Journal of Virology·Kristina E RehmRachel L Roper
Oct 22, 2009·The New England Journal of Medicine·Supachai Rerks-NgarmUNKNOWN MOPH-TAVEG Investigators
Dec 4, 2009·Virology·Kristina E RehmRachel L Roper
May 18, 2010·International Journal of Cancer. Journal International Du Cancer·Collin JacobsMax Schnurr
Jun 22, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nancy J NesslingerBrad H Nelson
Mar 29, 2012·Proceedings of the National Academy of Sciences of the United States of America·Kunle OdunsiElke Jäger
Jun 13, 2012·Methods in Molecular Biology·Rachel L Roper
Jan 31, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher T CampbellJeffrey C Gildersleeve
May 20, 2014·Vaccine·Gwendolyn J B JonesRachel L Roper
Jun 6, 2014·Journal of Virology·Adam R HerspergerLaurence C Eisenlohr
Jul 22, 2014·International Journal of Cancer. Journal International Du Cancer·Suvi ParviainenAkseli Hemminki
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 8, 2015·The Journal of Microbiology·Manbok Kim
Apr 9, 2015·Viruses·Lucas Sánchez-SampedroMariano Esteban
May 30, 2015·The Journal of General Virology·Clare FleischauerRachel L Roper
Mar 5, 2016·Journal of Experimental & Clinical Cancer Research : CR·Emmanuel ZervosRachel L Roper
Mar 16, 2016·Current Opinion in Oncology·Lisa M CordesRavi A Madan
Nov 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Raffit HassanIra Pastan

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
ELISA
dissection
glycosylation
flow cytometry

Software Mentioned

Genemed

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.